Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Conditions: Endometrial Cancer; Cancer of Endometrium; Carcinoma of Endometrium; Endometrial Carcinoma Interventions: Biological: AdHER2DC vaccine; Biological: Pembrolizumab; Biological: N-803; Drug: Lenvatinib; Device: PATHWAY HER2 (4B5) assay Sponsors: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials